STIBOCAPTATE

Details

Stereochemistry	MIXED
Molecular Formula	C12H12O12S6Sb2
Molecular Weight	784.126
Optical Activity	UNSPECIFIED
Defined Stereocenters	0 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C(S[Sb]1SC(C(S1)C(O)=O)C(O)=O)C(S[Sb]2SC(C(S2)C(O)=O)C(O)=O)C(O)=O

InChI

InChIKey=WRIDGMJGKDWAJY-UHFFFAOYSA-H

InChI=1S/3C4H6O4S2.2Sb/c3*5-3(6)1(9)2(10)4(7)8;;/h3*1-2,9-10H,(H,5,6)(H,7,8);;/q;;;2*+3/p-6

HIDE SMILES / InChI

Description
Sources: http://www.who.int/selection_medicines/committees/expert/18/applications/succimer.pdf

Succimer is an analogue of dimercaprol, and has replaced dimercaprol as one of the main antidotes used in the management of poisoning by lead and other heavy metals. The advantages of succimer are that it is effective by oral administration because it is soluble in water, it is well-tolerated, has relatively low toxicity and can be given at the same time as iron supplements to treat iron deficiency anaemia. It does not cause significant increase in urinary excretion of essential minerals unlike the other widelyused lead chelating agent, sodium calcium EDTA.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Lead 16 Target ID: CHEMBL2364029 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019998s013lbl.pdf	Chelating Agent 142

Conditions

Condition	Modality	Targets	Highest Phase	Product
Lead poisoning in children 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019998s013lbl.pdf	Curative		Approved 8429	CHEMET Approved Use For the treatment of lead poisoning in pediatric patients with blood lead levels above 45 ug/dL. Launch Date 1993

C_max

Value	Dose	Co-administered	Analyte	Population
25.3 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7716789/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:		SUCCIMER plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
55 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7588486/	10 mg/kg bw single, oral dose: 10 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:		STIBOCAPTATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
318 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7716789/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:		SUCCIMER plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
2 day DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019998s013lbl.pdf	single, oral	SUCCIMER blood	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
9.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7716789/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	SUCCIMER plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7588486/	10 mg/kg bw single, oral dose: 10 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	STIBOCAPTATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	OAT1 326

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
OAT1 326	substrate 3367 Sources: https://www.tandfonline.com/doi/full/10.1080/24734306.2020.1870077	weak

PubMed

Title	Date	PubMed
Angiotensin converting enzyme gene polymorphism in primary vesicoureteral reflux.	2001 Aug	11519895
Effect of dithiol chelating agents on [3H]MK-801 and [3H]glutamate binding to synaptic plasma membranes.	2001 Dec	11885782
Effects of Lewisite on cell membrane integrity and energy metabolism in human keratinocytes and SCL II cells.	2001 Jun 21	11516523
Associations of tibia lead, DMSA-chelatable lead, and blood lead with measures of peripheral nervous system function in former organolead manufacturing workers.	2001 Mar	11241558
Is it truly dementia?	2001 Mar 3	11247553
The effects of succimer chelation therapy on auditory function in rhesus monkeys.	2001 Nov-Dec	11792533
The effects of elevated blood lead levels and succimer chelation therapy on physical growth in developing rhesus monkeys.	2001 Sep	11534961
Lipoic acid in combination with a chelator ameliorates lead-induced peroxidative damages in rat kidney.	2002 Aug	12185410
Acute renal damage in infants after first urinary tract infection.	2002 Jul	12172762
Reflux nephropathy in transplants.	2002 Jul	12172759
[Metal poisoning].	2003	12813482
Reversal of cadmium induced oxidative stress by chelating agent, antioxidant or their combination in rat.	2003 Dec 10	14580892
The efficacy of monoisoamyl ester of dimercaptosuccinic acid in chronic experimental arsenic poisoning in mice.	2003 Jan	12635830
The role of oxidative stress in the in vitro induction of micronuclei by pesticides in mouse lung fibroblasts.	2003 Mar	12621067
Successful ways to increase retention in a longitudinal study of lead-exposed children.	2003 Nov	14679710
Resistive index in febrile urinary tract infections: predictive value of renal outcome.	2004 Feb	14685837
2,3-Dimercaptopropanol, 2,3-dimercaptopropane-1-sulfonic acid, and meso-2,3-dimercaptosuccinic acid inhibit delta-aminolevulinate dehydratase from human erythrocytes in vitro.	2004 Mar	15016592

Sample Use Guides

In Vivo Use Guide

10 mg/kg or 350 mg/m2 every eight hours for five days

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

STIBOCAPTATE

Common Name

English

SUCCINIC ACID, 2,3-DIMERCAPTO-, CYCLIC THIOANTIMONATE(III), S,S-DIESTER WITH 2,3-DIMERCAPTOSUCCINIC ACID

Common Name

English

ASTIBAN ACID

Common Name

English

1,3,2-DITHIASTIBOLANE-4,5-DICARBOXYLIC ACID, 2,2'-((1,2-DICARBOXY-1,2-ETHANEDIYL)BIS(THIO))BIS-

Common Name

English

Code System Code Type Description

ECHA (EC/EINECS)

217-858-9